Despite our promising findings with platinum-based therapies and EGFR inhibitors, there is still a high percentage of patients who may not respond to these therapies [4, 22], highlighting the necessity for novel therapies in lung cancer. This evidence concerns the gene EGFR and lung carcinoma.